shengbing zang

Dr. shengbing zang

pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2024 in Drug Resistance Updates
Verified
Journal Article
Closed access
KCKai-Lin Chen
Kai-Lin Chen
SHSai-Wei Huang
Sai-Wei Huang
JYJi-Jin Yao
Ji-Jin Yao
SHShi-Wei He
Shi-Wei He
SGSha Gong
Sha Gong
NLNa Liu
Na Liu

11 October 2022 in OncoImmunology
Verified
Journal Article
Open access
FQFenglian Que
Fenglian Que
LZLihong Zhang
Lihong Zhang
TWTaoli Wang
Taoli Wang
MXMeifang Xu
Meifang Xu
WLWan Gen Li
Wan Gen Li
SZshengbing zang
shengbing zang
Angioimmunoblastic T-cell lymphoma (AITL) is a malignant hematologic tumor arising from T follicular helper (Tfh) cells. High-throughput genomic sequencing studies have shown that AITL is characterized by a novel highly recurring somatic mutation in RHOA, encoding p.Gly17Val (RHOA G17V). However, the specific role of RHOA G17V in AITL remains unknown. Here, we demonstrated that expression of Rhoa G17V in CD4+ T cells increased cell proliferation and induces Tfh cell specification associated with Pon2 upregulation through an NF-κB-dependent mechanism. Further, loss of Pon2 attenuated oncogenic function induced by genetic lesions in Rhoa. In addition, an abnormality of RHOA G17V mutation and PON2 expression is also detected in patients with AITL. Our findings suggest that PON2 associated with RHOA G17V mutation might control the direction of the molecular agents-based AITL and provide a new therapeutic target in AITL.

20 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LHLina Hu
Lina Hu
XZXuanye Zhang
Xuanye Zhang
HLHuifeng Li
Huifeng Li
SLSuxia Lin
Suxia Lin
SZshengbing zang
shengbing zang
Angioimmunoblastic T-cell lymphoma (AITL), a type of malignant lymphoma with unique genomic aberrations, significant clinicopathological features, and poor prognosis, is characterized by immune system dysregulation. Recent sequencing studies have identified recurrent mutations and interactions in tet methylcytosine dioxygenase 2 (TET2), ras homology family member A (RHOA), DNA methyltransferase 3 alpha (DNMT3A), and mitochondrial isocitrate dehydrogenase II (IDH2). Notably, since B-cell lymphomas are frequently observed along with AITL, this review first summarizes its controversial mechanisms based on traditional and recent views. Epigenetic regulation represented by TET2 plays an increasingly important role in understanding the multi-step and multi-lineage tumorigenesis of AITL, providing new research directions and treatment strategies for patients with AITL. Here, we review the latest advances in our understanding of AITL and highlight relevant issues that have yet to be addressed in clinical practice.

1 November 2019 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
MXMeifang Xu
Meifang Xu
FWFei Wang
Fei Wang
HCHong Chen
Hong Chen
LLLin Liu
Lin Liu
WLWenwen Liu
Wenwen Liu
SZshengbing zang
shengbing zang
Objective Angioimmunoblastic T cell lymphoma (AITL) is an aggressive form of non-Hodgkin lymphoma derived from mature T cells. However, the underlying pathogenesis of AITL remains unresolved. We aimed to explore the role of FOXO1-mediated signaling in the tumorigenesis and progression of AITL. Methods FOXO1 expression was assessed using immunohistochemistry on a total of 46 AITL tissue samples. Retroviruses encoding FOXO1 shRNA were used to knockdown FOXO1 expression in CD4+ T cells. Flow cytometric assays analyzed the proliferation and survival of FOXO1 knockdown CD4+ T cells. Furthermore, we performed adoptive T-cell transfer experiments to identify whether inactivation of FOXO1 induced neoplastic follicular-helper T (Tfh) cell polarization and function. Results Patients with low FOXO1 protein levels were prone to have an advanced tumor stage (P = 0.049), higher ECOG ps (P = 0.024), the presence of bone marrow invasion (P = 0.000), and higher IPI (P = 0.035). Additionally, the survival rates of patients in the FOXO1 high-expression group were significantly better than those in the FOXO1 low-expression group (χ2 = 5.346, P = 0.021). We also observed that inactivation of FOXO1 increased CD4+ T cell proliferation and altered the survival and cell-cycle progression of CD4+ T cells. Finally, we confirmed that inactivation of FOXO1 induces Tfh cell programing and function. Conclusions Inactivation of FOXO1 in AITL plays a key role in the tumorigenesis and progression of AITL. We propose that FOXO1 expression could be a useful prognostic marker in AITL patients to predict poor survival, and to design appropriate therapeutic strategies.

3 July 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
SLSuxia Lin
Suxia Lin
XZXinke Zhang
Xinke Zhang
XLXiaoxuan Li
Xiaoxuan Li
CQChangfei Qin
Changfei Qin
LZLihong Zhang
Lihong Zhang
SZshengbing zang
shengbing zang
Background: In patients with squamous cell carcinoma of the cervix (SCCC), a squamous cell carcinoma (SqCC) in the lung represents either a second primary tumor or metastasis. This distinction between second primary tumors and lung metastases in patients with SCCC significantly influences patient prognosis and therapy. Here, we aimed to differentiate second primary tumors from lung metastases in patients with SCCC by exploring the HPV status in SqCCs involving the lung within a large cohort.Methods: P16 expression was assessed using immunohistochemistry on tissue microarrays including a total of 415 primary lung SqCCs and 21 lung SqCCs with prior SCCC. Following this, we performed HPV DNA typing and the sensitive RNAscope in situ method to screen all the cases for HPV E6/E7 expression, which is a more reliable indicator of transcriptively active HPV in tumor cells.Results: The p16 positive expression rate was 13.7% (57/415) in primary lung SqCCs, but HPV DNA was not detected in any of the 57 primary lung SqCC cases that positively expressed p16. In contrast, HPV DNA was detected in all cases (21/21) with prior SCCC. Consistently, all 21 lung SqCCs with prior SCCC (21/21) showed extensive HPV16 E6/E7 expression. In striking contrast, none of the primary lung SqCCs (0/415) had a detectable RNAscope signal.Conclusions: HPV does not seem to play a role in the development of primary lung SqCCs. HPV detection may be helpful in distinguishing second primary tumors from lung metastases in patients with SCCC.

28 July 2023 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
XLXiaoxuan Li
Xiaoxuan Li
YLYihong Ling
Yihong Ling
LHLina Hu
Lina Hu
LZLihong Zhang
Lihong Zhang
SLSuxia Lin
Suxia Lin
SZshengbing zang
shengbing zang
The etiologic link between HPV and lung cancer is still controversial. PubMed and Cochrane databases were searched from inception to December 2020 to identify studies on the infection of HPV in lung cancer. We calculated the attributable proportion of HPV in lung cancer by pooling the infection of cases positive for both HPV DNA and biomarker of carcinogenesis that may be induced by HPV (E6/E7 mRNA or p16INK4a). A total of 117 studies, comprising data of 12,616 lung cancer cases from 22 countries across five continents, were included. The overall HPV DNA positivity in primary lung cancer cases worldwide was 16.4% (95% CI 12.7-20.5). HPV DNA positivity of lung cancer varied significantly by pathological type and geographic region. Notably, the expression rate of p16INK4a is significantly higher than the positivity of HPV DNA and of HPV E6/E7 mRNA (P < 0.05). The estimate of HPV attributable proportion defined by expression of E6/E7 mRNA was 0 and of p16INK4a was 7.3%. The data in this systematic review is robust enough to contradict the possible participation of HPV in lung cancer carcinogenesis. Prophylactic vaccines targeting HPV cannot have the potential to prevent lung cancer.